Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome
Open Access
- 28 May 2012
- journal article
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 7 (1) , 24
Abstract
Background: Fragile X syndrome (FXS) is caused by the absence of the mRNA-binding protein Fragile X mental retardation protein (FMRP), encoded by the Fmr1 gene. Overactive signaling by group 1 metabotropic glutamate receptor (Grp1 mGluR) could contribute to slowed synaptic development and other symptoms of FXS. Our previous study has identified that facilitation of synaptic long-term potentiation (LTP) by D1 receptor is impaired in Fmr1 knockout (KO) mice. However, the contribution of Grp1 mGluR to the facilitation of synaptic plasticity by D1 receptor stimulation in the prefrontal cortex has been less extensively studied. Results: Here we demonstrated that DL-AP3, a Grp1 mGluR antagonist, rescued LTP facilitation by D1 receptor agonist SKF81297 in Fmr1KO mice. Grp1 mGluR inhibition restored the GluR1-subtype AMPA receptors surface insertion by D1 activation in the cultured Fmr1KO neurons. Simultaneous treatment of Grp1 mGluR antagonist with D1 agonist recovered the D1 receptor signaling by reversing the subcellular redistribution of G protein-coupled receptor kinase 2 (GRK2) in the Fmr1KO neurons. Treatment of SKF81297 alone failed to increase the phosphorylation of NR2B-containing N-methyl D-aspartate receptors (NMDARs) at Tyr-1472 (p-NR2B-Tyr1472) in the cultures from KO mice. However, simultaneous treatment of DL-AP3 could rescue the level of p-NR2B-Tyr1472 by SKF81297 in the cultures from KO mice. Furthermore, behavioral tests indicated that simultaneous treatment of Grp1 mGluR antagonist with D1 agonist inhibited hyperactivity and improved the learning ability in the Fmr1KO mice. Conclusion: The findings demonstrate that mGluR1 inhibition is a useful strategy to recover D1 receptor signaling in the Fmr1KO mice, and combination of Grp1 mGluR antagonist and D1 agonist is a potential drug therapy for the FXS.Keywords
This publication has 65 references indexed in Scilit:
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's DiseaseThe Journal of Neuroscience, 2011
- Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndromeProceedings of the National Academy of Sciences, 2011
- Enhanced synaptic long-term potentiation in the anterior cingulate cortex of adult wild mice as compared with that in laboratory miceMolecular Brain, 2009
- FMRP Acts as a Key Messenger for Dopamine Modulation in the ForebrainNeuron, 2008
- Dopamine and working memory mechanisms in prefrontal cortexThe Journal of Physiology, 2007
- Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X miceProceedings of the National Academy of Sciences, 2007
- Restoration of Long-Term Potentiation in Middle-Aged Hippocampus After Induction of Brain-Derived Neurotrophic FactorJournal of Neurophysiology, 2006
- Deficits in Trace Fear Memory and Long-Term Potentiation in a Mouse Model for Fragile X SyndromeJournal of Neuroscience, 2005
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004
- Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndromeCell, 1991